Current Report No.: 10/2026
Date: 01.04.2026 r.
Legal basis: Article 17(1) of the MAR Regulation – confidential information.
The Management Board of Medicalgorithmics S.A. (the “Company”, “Medicalgorithmics”) announces that on March 31st 2026 the Company entered into an annex to the agreement (the “Agreement”) with a partner from Israel (the “Contractor”), extending the scope of the existing cooperation with new products and introducing further significant changes to the Agreement concerning, among others, payment terms, and price.
Under the amended Agreement, Medicalgorithmics will additionally provide the Contractor with the DeepRhythmPlatform (DRP) software using DRAI algorithms to analyze and classify ECG signals and a software solution for autonomous assessment of coronary artery disease (CAD) – VCAST (“ECG Software”) together with the right to use under the Agreement. In addition, Medicalgorithmics granted the Contractor the exclusive right to sell, market and distribute the Product (Pocket ECG and Kardiobeat.ai devices) for the purpose of diagnostics in Israel and West Bank _ Palestine. The exclusivity provisions do not apply to entities operating in multiple international markets or to non-commercial clinical trial-related collaborations.
In accordance with the terms of the Agreement, for the Product and related services provided by the Company to the Contractor, including the ECG Software, the Contractor shall pay remuneration (specified in EUR) for the devices (according to the unit price) and for each month of use of the ECG Software according to monthly flat fees for monitoring or according to the unit price per examination (the price depends on the type of ECG Software). In addition, the Parties have agreed on individual terms and conditions with respect to the entity indicated in the Agreement and an individual price annex with regard to DRP software and Kardiobeat.ai devices. Pursuant to the Agreement, the Parties have agreed on the terms of the order for Kardiobeat.ai devices, which will be accepted for execution by the Company after the Contractor has made a 100% prepayment for the order. The remaining provisions of the annex do not differ from the practices commonly used on the market for this type of products and services. The Management Board informs that the Company has received an order from the Contractor for Kardiobeat.ai devices based on the new business arrangements contained in the annex. The value of the remuneration for the order will amount to PLN 654 thousand in 2026.
The execution of the Agreement (annex) constitutes a significant step in the implementation of the Company’s strategy, as presented in current report No. 16/2023 dated 19 June 2023, which aims to substantially increase the Company’s revenues and profitability and to generate positive cash flows. In the Management Board’s opinion, the execution of the Agreement will strengthen the Company’s market position, open up new growth opportunities in the Israeli market and, consequently, have a positive impact on its financial results in the coming periods.
The values in EUR indicated in this report have been converted into PLN according to the exchange rate 4.29 EUR/PLN.